Submit to Medicina Review for Medicina Propose a Special Issue

Journal Browser

► Journal Browser

The Molecular Mechanism and Prevention Strategy of Osteoporosis

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: closed (25 May 2023) | Viewed by 7200

Share This Special Issue

Special Issue Editors

Prof. Dr. Minqi Li

E-Mail Website
Guest Editor

1. Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan 250012, China
2. Department of Bone Metabolism, School of Stomatology, Shandong University, Jinan 250012, China
Interests: bone metabolism; osteoporosis; bone remolding; oral; oral squamous cell carcinoma

Dr. Hongrui Liu

E-Mail Website
Guest Editor

Dr. Tomoka Hasegawa

E-Mail Website
Guest Editor

Department of Developmental Biology of Hard Tissue, Graduate School of Dental Medicine, Hokkaido University, Sapporo 060-8586, Japan
Interests: bone cell

Special Issue Information

Dear Colleagues,

Due to the ageing population, osteoporosis incidence is rapidly increasing and gradually becoming a public health problem. Classical theories hold that osteoporosis is essentially bone remodeling disorder caused by estrogen deficiency/aging or secondary to diseases/drugs. With the in-depth understanding of the intricate bone microenvironment, a few novel fields have been proposed such as osteoimmunology, senescence, oxidative stress, and so on. However, the molecular mechanism of osteoporosis has not yet been fully recognized. Common drugs for osteoporosis, including bisphosphonates, denosumab, teriparatide, have not generated ideal therapeutic effects. Also, targeted treatments based on its pathological characteristics have not yet been identified. Therefore, we are interested in developing a special issue about ‘The molecular mechanism and prevention strategy of osteoporosis’. The aim of this issue is to provide a platform for scientists and academicians all over the world to promote, share and discuss various new issues and developments about osteoporosis. This issue will contain original research, review and perspective manuscripts. From this issue, the identifying of new checkpoints may provide excellent opportunities to develop valuable therapies for osteoporosis.

Prof. Dr. Minqi Li
Dr. Hongrui Liu
Dr. Tomoka Hasegawa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

osteoporosis
molecular mechanism
prevention strategy
drugs development
osteoimmunology
oxidative stress
senescence

Published Papers (4 papers)

Download All Papers

Research

Jump to: Other

17 pages, 10665 KiB

Open AccessArticle

The Synergistic Effect of Zuogui Pill and Eldecalcitol on Improving Bone Mass and Osteogenesis in Type 2 Diabetic Osteoporosis

by Tuo Shi, Ting Liu, Yuying Kou, Xing Rong, Lingxiao Meng, Yajun Cui, Ruihan Gao, Sumin Hu and Minqi Li

Medicina 2023, 59(8), 1414; https://doi.org/10.3390/medicina59081414 - 03 Aug 2023

Cited by 2 | Viewed by 1259

Abstract

Background and Objectives: The incidence of diabetic osteoporosis, an important complication of diabetes mellitus, is increasing gradually. This study investigated the combined effect of the Zuogui pill (ZGP) and eldecalcitol (ED-71), a novel vitamin D analog, on type 2 diabetic osteoporosis (T2DOP) and explored their action mechanism. Materials and Methods: Blood glucose levels were routinely monitored in db/db mice while inducing T2DOP. We used hematoxylin and eosin staining, Masson staining, micro-computed tomography, and serum biochemical analysis to evaluate changes in the bone mass and blood calcium and phosphate levels of mice. Immunohistochemical staining was performed to assess the osteoblast and osteoclast statuses. The MC3T3-E1 cell line was cultured in vitro under a high glucose concentration and induced to undergo osteogenic differentiation. Quantitative real-time polymerase chain reaction, Western blot, immunofluorescence, ALP, and alizarin red staining were carried out to detect osteogenic differentiation and PI3K–AKT signaling pathway activity. Results: ZGP and ED-71 led to a dramatic decrease in blood glucose levels and an increase in bone mass in the db/db mice. The effect was strongest when both were used together. ZGP combined with ED-71 promoted osteoblast activity and inhibited osteoclast activity in the trabecular bone region. The in vitro results revealed that ZGP and ED-71 synergistically promoted osteogenic differentiation and activated the PI3K–AKT signaling pathway. The PI3K inhibitor LY294002 or AKT inhibitor ARQ092 altered the synergistic action of both on osteogenic differentiation. Conclusions: The combined use of ZGP and ED-71 reduced blood glucose levels in diabetic mice and promoted osteogenic differentiation through the PI3K–AKT signaling pathway, resulting in improved bone mass. Our study suggests that the abovementioned combination constitutes an effective treatment for T2DOP. Full article

(This article belongs to the Special Issue The Molecular Mechanism and Prevention Strategy of Osteoporosis)

► Show Figures

Graphical abstract

16 pages, 16224 KiB

Open AccessArticle

Immunolocalization of Enzymes/Membrane Transporters Related to Bone Mineralization in the Metaphyses of the Long Bones of Parathyroid-Hormone-Administered Mice

by Takahito Mae, Tomoka Hasegawa, Hiromi Hongo, Tomomaya Yamamoto, Shen Zhao, Minqi Li, Yutaka Yamazaki and Norio Amizuka

Medicina 2023, 59(6), 1179; https://doi.org/10.3390/medicina59061179 - 20 Jun 2023

Cited by 1 | Viewed by 1250

Abstract

The present study aimed to demonstrate the immunolocalization and/or gene expressions of the enzymes and membrane transporters involved in bone mineralization after the intermittent administration of parathyroid hormone (PTH). The study especially focused on TNALP, ENPP1, and PHOSPHO1, which are involved in matrix vesicle-mediated mineralization, as well as PHEX and the SIBLING family, which regulate mineralization deep inside bone. Six-week-old male mice were subcutaneously injected with 20 μg/kg/day of human PTH (1–34) two times per day (n = 6) or four times per day (n = 6) for two weeks. Additionally, control mice (n = 6) received a vehicle. Consistently with an increase in the volume of the femoral trabeculae, the mineral appositional rate increased after PTH administration. The areas positive for PHOSPHO1, TNALP, and ENPP1 in the femoral metaphyses expanded, and the gene expressions assessed by real-time PCR were elevated in PTH-administered specimens when compared with the findings in control specimens. The immunoreactivity and/or gene expressions of PHEX and the SIBLING family (MEPE, osteopontin, and DMP1) significantly increased after PTH administration. For example, MEPE immunoreactivity was evident in some osteocytes in PTH-administered specimens but was hardly observed in control specimens. In contrast, mRNA encoding cathepsin B was significantly reduced. Therefore, the bone matrix deep inside might be further mineralized by PHEX/SIBLING family after PTH administration. In summary, it is likely that PTH accelerates mineralization to maintain a balance with elevated matrix synthesis, presumably by mediating TNALP/ENPP1 cooperation and stimulating PHEX/SIBLING family expression. Full article

(This article belongs to the Special Issue The Molecular Mechanism and Prevention Strategy of Osteoporosis)

► Show Figures

Figure 1

11 pages, 328 KiB

Open AccessArticle

Association between Serum Oxytocin, Bone Mineral Density and Body Composition in Chinese Adult Females

by Wei-Jia Yu, Hong-Li Shi, Xiao-Qing Wu, Yan-Ping Du, Hui-Lin Li, Wen-Jing Tang, Min-Min Chen, Xue-Mei Zhang, Liu Shen and Qun Cheng

Medicina 2022, 58(11), 1625; https://doi.org/10.3390/medicina58111625 - 11 Nov 2022

Cited by 3 | Viewed by 1426

Abstract

Background and Objectives: Oxytocin (OT) is a neuropeptide hormone which is known for its classical effects in pregnancy and lactation. Recently, growing evidence demonstrated a close relation between OT and bone. The present study aimed to explore the relationship between OT, bone and osteoporosis risk in Chinese adult females. Materials and Methods: in total, 149 adult females were enrolled. The serum OT levels were measured using ELISA kits. Bone mineral density (BMD) and body composition were measured by dual-energy X-ray absorptiometry (DXA). The study subjects were divided into two groups according to their menopause status and then divided into tertiles based on their serum OT level. Results: Serum OT, serum estradiol and BMD at three skeletal sites were significantly higher in the premenopausal group than in the postmenopausal group (p < 0.001, p = 0.008 and p < 0.001, respectively). In the tertile analysis, relative to tertile 1, significant associations were found for tertile 3 for OT levels and higher BMD in the femoral neck and total hip, in both pre- and postmenopausal groups. Using logistic regression analysis, tertile 3 appeared less likely to have low-BMD osteoporosis than tertile 1 (OR = 0.257, 95% CI = 0.073, 0.910). In multivariate stepwise regression analysis, OT and total lean mass were two positive determinants of BMD in the femoral neck and total hip in the premenopausal group (adjusted R² for the model = 0.232 and 0.199, respectively; both p < 0.001). Conclusion: Our study demonstrated positive associations between serum OT levels and BMD in a Chinese (non-Caucasian) population. OT appeared to be more strongly associated with hip BMD in premenopausal females. These results may suggest a protective role and potential therapeutic use of OT in osteoporosis, especially for premenopausal women. Full article

(This article belongs to the Special Issue The Molecular Mechanism and Prevention Strategy of Osteoporosis)

Other

Jump to: Research

13 pages, 3322 KiB

Open AccessSystematic Review

Comparison of the Effects of Metformin and Thiazolidinediones on Bone Metabolism: A Systematic Review and Meta-Analysis

by Ru-Dong Chen, Cong-Wen Yang, Qing-Run Zhu, Yu Li, Hai-Feng Hu, Da-Chuan Wang and Shi-Jie Han

Medicina 2023, 59(5), 904; https://doi.org/10.3390/medicina59050904 - 08 May 2023

Viewed by 2758

Abstract

Objectives: Studies have shown that people with diabetes have a high risk of osteoporosis and fractures. The effect of diabetic medications on bone disease cannot be ignored. This meta-analysis aimed to compare the effects of two types of glucose-lowering drugs, metformin and thiazolidinediones (TZD), on bone mineral density and bone metabolism in patients with diabetes mellitus. Methods: This systematic review and meta-analysis were prospectively registered on PROSPERO, and the registration number is CRD42022320884. Embase, PubMed, and Cochrane Library databases were searched to identify clinical trials comparing the effects of metformin and thiazolidinediones on bone metabolism in patients with diabetes. The literature was screened by inclusion and exclusion criteria. Two assessors independently assessed the quality of the identified studies and extracted relevant data. Results: Seven studies involving 1656 patients were finally included. Our results showed that the metformin group had a 2.77% (SMD = 2.77, 95%CI [2.11, 3.43]; p < 0.00001) higher bone mineral density (BMD) than the thiazolidinedione group until 52 weeks; however, between 52 and 76 weeks, the metformin group had a 0.83% (SMD = −0.83, 95%CI: [−3.56, −0.45]; p = 0.01) lower BMD. The C-terminal telopeptide of type I collagen (CTX) and procollagen type I N-terminal propeptide (PINP) were decreased by 18.46% (MD = −18.46, 95%CI: [−27.98, −8.94], p = 0.0001) and 9.94% (MD = −9.94, 95%CI: [−16.92, −2.96], p = 0.005) in the metformin group compared with the TZD group. Full article

(This article belongs to the Special Issue The Molecular Mechanism and Prevention Strategy of Osteoporosis)

► Show Figures